AMIX - AMIX

Ultime notizie per Autonomix Medical (NASDAQ:AMIX) Azioni

Autonomix Medical

Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.

Autonomix Medical Inc

Rosenblatt analyst Kevin Cassidy maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Buy and maintains $130 price target.

News

Price Target

Analyst Ratings

Rosenblatt Maintains Buy on Seagate Tech Hldgs, Maintains $130 Price Target

Sol-Gel Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLGL#NASDAQ">SLGL</a>) reported quarterly losses of $(3.20) per share. This is a 39.13 percent decrease over losses of $(2.30) per share from the same period last year. The company reported quarterly sales of $1.03 million which missed the analyst consensus estimate of $1.20 million by 14.08 percent. This is a 121.24 percent increase over sales of $466.00 thousand the same period last year.

Earnings

Earnings Misses

SLGL

Sol-Gel Technologies Q1 EPS $(3.20) Vs. (2.30) Prior Year, Sales $1.03M Miss $1.20M Estimate

D. Boral Capital analyst Jason Kolbert maintains Nano X Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNOX#NASDAQ">NNOX</a>) with a Buy and lowers the price target from $15 to $10.

NNOX

D. Boral Capital Maintains Buy on Nano X Imaging, Lowers Price Target to $10

GSK's Blenrep (Belantamab Mafodotin) Received Positive Opinion Form The EUs CHMP For Treatment Of Relapsed Or Refractory Multiple Myeloma In Adults Aged 60+

PHUN

Phunware Unveils Hospitality AI Features To Enhance Mobile Guest Engagement, Plans Next-Gen App Innovation Talks

Bank of America Corporation Announced That It Will Redeem On June 12, 2025 All CHF375,000,000 Principal Amount Outstanding Of Its 0.2525% Senior Notes, Due June 12

Legal

BABA

Alibaba Concluded Some Products May Contain 3TG From Covered Countries, But Finds No Evidence The 3TG Financed Armed Groups

PPTA

Perpetua Resources Submits Formal Application To Export-Import Bank of the United States to Finance Stibnite Gold Project, Company Seeks $2B Financing; Aims To Boost U.S. Antimony Supply Amid Strategic Minerals Push

OKLO: 24% &#x7C; <a href="https://www.benzinga.com//node/45577517">Shares of OKLO and nuclear-linked stocks are trading higher amid report that President Trump to sign orders to boost nuclear power as soon as Friday.</a>
&nbsp;
BCAX: -36% &#x7C; <a href="https://www.benzinga.com//node/45576722">Bicara Therapeutics shares are trading lower after the company announced a publication of phase 1/1b trial data for ficerafusp alfa showing mixed results, with median survival still unreached and limited clarity on long-term efficacy.</a>
&nbsp;
IMMX: -20% &#x7C; <a href="https://www.benzinga.com//node/45577764">IMMX stock has given up its prior gain. Immix Biopharma shares were trading higher after the company announced the publication of cell therapy NXC-201 Abstract #7508, selected for oral presentation at the 2025 American Society of Clinical Oncology Annual Meeting.</a>

Movers

Trading Ideas

BCAX

IMMX

OKLO

Market-Moving News for May 23rd

Memorandum aims to integrate IonQ's quantum technology into South Korea's high-performance computing infrastructure, fueling R&amp;D, talent development, and ecosystem growth.
IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), a leading commercial quantum computing and networking company, today announced the signing of a memorandum of understanding (MoU) with the Korea Institute of Science and Technology Information (KISTI), a leading national science and technology research institute and supercomputing center. The memorandum marks a significant expansion of IonQ's long standing relationship with South Korea's government, academic and industry sectors, aligning efforts intended to accelerate the national development of quantum science and industry.
Under the terms of the MoU, IonQ and KISTI will collaborate in four key areas: advanced infrastructure access, education, talent and knowledge exchange as well as collaboration to expand market opportunities. The two organizations will work together with the intent to introduce quantum systems into KISTI and plan to integrate these systems with KISTI's high-performance computing (HPC) infrastructure.
IonQ and KISTI also plan to collaborate on joint initiatives for talent upskilling including internships and training programs to strengthen the quantum computing research community in South Korea.

IONQ

IonQ Signs MoU With KISTI To Integrate IonQ's Quantum Technology Into South Korea's Computing Infrastructure, Fueling R&D, Talent Development, And Ecosystem Growth

HC Wainwright &amp; Co. analyst Yi Chen maintains Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) with a Buy and lowers the price target from $15 to $12.

KALA

HC Wainwright & Co. Maintains Buy on Kala Bio, Lowers Price Target to $12

KDLY

KindlyMD Changes NASDAQ Ticker To 'NAKA' Effective May 23, Reflecting Strategic Pivot Via Proposed Merger With Bitcoin-Focused Nakamoto

Instil And ImmuneOnco To Present Clinical Trial Updates And Insights On PD-(L)1xVEGF At ASCO Meeting

Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses
New analyses confirm that pelareorep primes the TME to allow circulating tumor-infiltrating lymphocytes (TILs) in the blood to attack tumors
Pre-existing TIL clones in plasma may correlate positively with tumor shrinkage in pancreatic cancer
SAN DIEGO and CALGARY, AB, May 23, 2025 /PRNewswire/ -- Oncolytics Biotech&#xAE;&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>), a leading clinical-stage company specializing in immunotherapy for oncology, today announced new data from the Phase I/II GOBLET clinical trial in a poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation highlights pelareorep's mechanism of action in pancreatic ductal adenocarcinoma (PDAC), offering new insights into how this immunotherapy stimulates multiple arms of the immune system and primes tumors for treatment.

ONCY

TSX:ONC

Oncolytics Biotech To Present New Data From Phase I/II GOBLET Clinical Trial At 2025 ASCO Annual Meeting

Invivyd, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>), today announced that PEMGARDA&#xAE; (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network&#xAE; (NCCN&#xAE;) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. NCCN joins the Infectious Disease Society of America (IDSA) that updated its COVID-19 guidelines in August 2024 to recommend the use of PEMGARDA (pemivibart) for pre-exposure prophylaxis (PrEP) in moderately to severely immunocompromised adults and adolescents (aged 12 or older) at risk for progression to severe COVID-19 when predominant regional variants are susceptible to pemivibart.
This inclusion in the NCCN Guidelines recognizes PEMGARDA as a potential option for PrEP against COVID-19 in patients with B-cell malignancies. Immunocompromised patients may not mount an adequate immune response to vaccination.

IVVD

Invivyd's PEMGARDA Added to Cancer Guidelines for COVID-19 Protection in Immunocompromised Patients

TLSA

Tiziana Life Sciences Highlights Clinical Progress On Intranasal Alzheimer's Therapy With National Spotlight

Guidance

AIOT

Powerfleet Sees Prelim. FY25 Total Revenue ~$362.5M, Up 25% YoY; Sees FY26 Revenue Growth 20-25%

VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>), a global digital operator ("VEON" or "the Company"), announces that it has now secured all regulatory approvals for its strategic partnership with Engro Corporation Limited ("Engro Corp") for the pooling and management of telecommunications infrastructure assets in Pakistan. The partnership, initially announced on December 5, 2024, is expected to enhance the efficiency of infrastructure and digital investments in the country, in line with Pakistan's digital ambitions.
Under the agreement, VEON's infrastructure assets housed under Deodar (Private) Limited, wholly owned by VEON through its subsidiary Pakistan Mobile Communications Limited, will vest into Engro Connect, an Engro Corp's subsidiary, via a scheme of arrangement. The companies have secured the necessary regulatory approvals, including from the Competition Commission of Pakistan, the Pakistan Telecommunication Authority, and the Islamabad High Court. The scheme of arrangement and related settlements are expected to be completed in June.

VEON

VEON Now Secures All Regulatory Approvals For Strategic Partnership With Engro Corp. For Pooling And Management Of Telecommunications Infrastructure Assets In Pakistan

OpenAI,&nbsp;Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>),&nbsp;Nvidia&nbsp;Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Cisco Systems, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>), and Group 42 Holding announced their <a target="_blank" href="https://www.benzinga.com/topic/project-stargate" rel="noreferrer noopener">partnership to build</a> Stargate UAE on Thursday.
Stargate UAE is a next-generation AI infrastructure cluster that will run in the newly established 5-gigawatt UAE–U.S. AI Campus <a target="_blank" href="https://group.softbank/en/news/press/20250522" rel="noreferrer noopener">in Abu Dhabi</a>.
G42 will build Stargate UAE, a 1-gigawatt compute cluster, and OpenAI and Oracle will operate it.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45389466/softbank-books-3-6-billion-profit-on-arm-bytedance-gains-while-ai-bets-face-trade-policy-hurdles" rel="noreferrer noopener">SoftBank Books $3.6 Billion Profit On Arm, ByteDance Gains While AI Bets Face Trade Policy Hurdles</a>
The collaboration will also include Cisco, offering its zero-trust security and AI-ready connectivity, SoftBank Group, and Nvidia, which will supply the latest Nvidia Grace Blackwell GB300 systems.
The first 200-megawatt AI cluster will likely go live in 2026. Stargate UAE will accelerate scientific discovery and drive innovation across industries ranging from healthcare and energy to finance and transportation, fueling future economic growth and national development.
The full UAE–U.S. AI infrastructure campus, which spans 10 square miles, is the largest such deployment outside the U.S. It will provide 5 gigawatts of AI data center capacity and regional compute resources.
The facility will be powered by nuclear, solar, and natural gas to minimize carbon emissions. It will also house a science park driving innovation, talent development, and sustainable compute infrastructure.
Jensen Huang, founder and CEO of Nvidia, said, &#8220;AI is the most transformative force of our time. With Stargate UAE, we are building the AI infrastructure to power the country&#8217;s bold vision – to empower its people, grow its economy, and shape its future.&#8221;
Chuck Robbins, chair and CEO of Cisco, said, &#8220;Cisco is proud to join Stargate UAE to advance groundbreaking AI innovation in the UAE and around the world. By embedding our secure AI-optimized networking fabric for this international deployment, we&#8217;re building smart, secure and energy-efficient networks that will turn intelligence into impact at global scale.&#8221;
&#8220;By establishing the world&#8217;s first Stargate outside of the U.S. in the UAE, we&#8217;re transforming a bold vision into reality. This is the first major milestone in our OpenAI for Countries initiative, our effort to work with allies and partners to build AI infrastructure around the world. It&#8217;s a step toward ensuring some of this era&#8217;s most important breakthroughs, safer medicines, personalized learning, and modernized energy, can emerge from more places and benefit the world,&#8221; Sam Altman, co-founder and CEO of OpenAI stated.
A <a target="_blank" href="https://www.benzinga.com/media/25/04/44873349/openai-and-softbanks-stargate-considers-major-uk-investment-to-fuel-ai-growth" rel="noreferrer noopener">report in April</a> indicated that Stargate&nbsp;is weighing a&nbsp;future investment in&nbsp;the U.K. to build the global infrastructure needed to support advanced artificial intelligence models.
The&nbsp;OpenAI&nbsp;and&nbsp;SoftBank-backed AI infrastructure joint venture is raising $100 billion in investment in AI infrastructure projects, which could reach $500 billion over the next four years.&nbsp;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45572996/apple-likely-to-open-llms-integrate-gemini-on-iphone-at-wwdc-analyst" target="_blank" rel="noreferrer noopener">Apple Likely To Open LLMs, Integrate Gemini On iPhone At WWDC: Analyst</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Tech

CSCO

NVDA

ORCL

SFTBF

SFTBY

Tech Titans Unite For Stargate UAE In AI Venture

Brookfield Corporation ("Brookfield") (NYSE:<a href="https://www.benzinga.com/stock/BN#NYSE">BN</a>, TSX:<a href="https://www.benzinga.com/stock/BN#TSX">BN</a>)&nbsp;today announced it has received approval from the Toronto Stock Exchange ("TSX") for the renewal of its normal course issuer bid to purchase up to 143,027,158 Class A Limited Voting Shares ("Class A Shares"), representing 10% of the public float of Brookfield's outstanding Class A Shares. Purchases under the bid will be made on the open market through the facilities of the TSX, the New York Stock Exchange ("NYSE"), and/or alternative trading systems. The period of the normal course issuer bid will extend from May 27, 2025 to May 26, 2026, or an earlier date should Brookfield complete its purchases. Brookfield will pay the market price at the time of acquisition for any Class A Shares purchased or such other price as may be permitted.

Buybacks

Brookfield Gets Green Light to Buy Back Up to 143M Shares Through 2026

Press Releases

Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain

Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR

Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor "What This Means" Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain

Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain

Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market

Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology

AMIX

Aethlon Medical

Bluejay Diagnostics

Biomerica

Co-Diagnostics

Ekso Bionics Holdings, Inc. - Common Stock

Ekso Bionics Holdings

GlucoTrack

HeartSciences

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Tech

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions

INVO Fertility

Know Labs

LogicMark

NanoVibronix

ENDRA Life Sciences

Nuwellis

Predictive Oncology

ReShape Lifesciences, Inc. - Common Stock

Reshape Lifesciences

SINTX Technologies

Strata Skin Sciences, Inc. - Common Stock

Strata Skin Sciences

Tivic Health Systems, Inc. - Common stock

Tivic Health Systems

Tenon Medical

Venus Concept

Catheter Precision

Xylo Technologies Ltd. - American Depositary Shares

Xylo Technologies

Maxim Group

Ladenburg Thalmann

Screenshot 2024-10-02 at 5.21.14 PM

Biotech

General

This Company Is Taking An Innovative, Non-Opioid Approach To Pain Management For Pancreatic Cancer

Screenshot 2024-07-11 at 9.17.30 PM

Autonomix&#39;s Trial Results Show Meaningful Reduction In Pain For Patients Suffering From Pancreatic Cancer

Screenshot 2024-06-12 at 6.28.14 PM

Movers & Shakers

Discover How This Company&#39;s Breakthrough Technology Might Be The Key To Transforming Pancreatic Cancer Pain Relief

Screenshot 2024-06-05 at 7.12.02 PM

This One Company Is Working On A Breakthrough Approach To Revolutionize Pain Management

Screenshot 2024-05-07 at 11.14.55 PM

Health Care

3000x More Sensitive Than What Is On The Market – This Technology Moves The Needle

Screenshot 2024-04-10 at 6.42.30 PM

Autonomix Medical (NASDAQ: AMIX) Is Cracking the Code Of The Peripheral Nervous System With Its Breakthrough Technology To Treat Diseases

The Nervous System Is Central To The Body, Yet Limited CNS Diagnostic Tools Exist – This Company Wants To Change That

Comments

Autonomix Medical

Notizie

Ultime notizie per Autonomix Medical (NASDAQ:AMIX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO